American Association for Cancer Research
ccr-23-1990_table_s2_suppts2.pdf (165.85 kB)

Table S2 from Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma

Download (165.85 kB)
journal contribution
posted on 2024-01-17, 08:20 authored by Minggui Pan, Maggie Yuxi Zhou, Chen Jiang, Zheyang Zhang, Nam Q. Bui, Jeffrey Bien, Amanda Siy, Ninah Achacoso, Aleyda V. Solorzano, Pamela Tse, Elaine Chung, Sachdev Thomas, Laurel A. Habel, Kristen N. Ganjoo

Demographics of patients with wt and mut CDKN2A.


Stanford University (SU)



To examine whether overall survival (OS) differs for male and female patients with advanced soft-tissue sarcoma (STS). The study included patients from Kaiser Permanente Northern California and Stanford Cancer Center with grade 2 and 3 locally advanced or metastatic STS whose tumor underwent next-generation sequencing. We used Cox regression modeling to examine association of sex and OS adjusting for other important factors. Among 388 eligible patients, 174 had leiomyosarcoma (LMS), 136 had undifferentiated pleomorphic sarcoma (UPS), and 78 had liposarcoma. OS for male versus female patients appeared to be slightly better among the full cohort [HR = 0.89; 95% confidence interval (CI), 0.66–1.20]; this association appeared to be stronger among the subsets of patients with LMS (HR = 0.76; 95% CI, 0.39–1.49) or liposarcoma (HR = 0.74; 95% CI, 0.32–1.70). Better OS for male versus female patients was also observed among all molecular subgroups except mutRB1 and mutATRX, especially among patients whose tumor retained wtTP53 (HR = 0.73; 95% CI, 0.44–1.18), wtCDKN2A (HR = 0.85; 95% CI, 0.59–1.23), wtRB1 (HR = 0.73; 95% CI, 0.51–1.04), and among patients whose tumor had mutPTEN (HR = 0.37; 95% CI, 0.09–1.62). OS also appeared to be better for males in the MSK-IMPACT and TCGA datasets. A fairly consistent pattern of apparent better OS for males across histologic and molecular subgroups of STS was observed. If confirmed, our results could have implications for clinical practice for prognostic stratification and possibly treatment tailoring as well as for future clinical trials design.

Usage metrics

    Clinical Cancer Research



    Ref. manager